Drug intelligence / Profile preview

BIFIDO multi-strain probiotic (SNUH)

Development stage: Unknown
Lead developer: Chambio
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This multi-strain probiotic is a live biotherapeutic product (LBP) developed and evaluated by Seoul National University Hospital in collaboration with BIFIDO Co., Ltd. for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). The formulation consists of four specific lyophilized bacterial strains: *Bifidobacterium bifidum* BGN4, *Bifidobacterium lactis* AD011, *Lactobacillus acidophilus* AD031, and *Lactobacillus casei* IBS041. Its mechanism of action involves the modulation of the gut microbiota, enhancement of the intestinal mucosal barrier, and the reduction of inflammation-related metabolites and pro-inflammatory cytokines. In a double-blind, randomized, placebo-controlled trial (NCT01637714), the administration of 40 billion colony-forming units (CFU) per day for eight weeks was shown to significantly improve abdominal pain and stool consistency in patients diagnosed according to Rome II criteria.

Brand names: Bifidus
Other names: Multi-strain probiotics (Seoul National University Hospital)BGN4 + AD011 + AD031 + IBS041 mixture

Beyond the preview

Go deeper on BIFIDO multi-strain probiotic (SNUH).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIFIDO multi-strain probiotic (SNUH).

Explore the full profile